Affinia Therapeutics competitors

Dr. Bruce A. Goldsmith is the Interim CEO at Civetta Therapeutics and Venture Partner at Deerfield Management. He joined Lycera as chief business officer in 2013 and brings more than 15 years of experience in the pharmaceutical and biotechnology industries. Most recently, he served as senior vice president corporate development at Allos Therapeutics, where he helped shape and manage corporate strategy and planning, financing transactions, business development and investor relations. While at Allos, Dr. Goldsmith led the successful sale of the company and, previously, executed a global collaboration for the co-development and commercialization of the company’s lead oncology asset outside of North America. Prior to joining Allos, Dr. Goldsmith served as vice president, strategic marketing at GPC Biotech. Previously, he held various strategic marketing and business development roles with the Johnson & Johnson family of companies, including roles as group product director, virology and global marketing leader, oncology. Dr. Goldsmith holds an M.B.A. from Columbia Business School, a Ph.D. in neuroscience from the University of Pennsylvania and his B.A. in biology from Colgate University.